NCT07189299View on ClinicalTrials.gov

Microdosing LSD in Women With Premenstrual Disorders

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 1, 2029

Study Completion Date

January 1, 2030

Conditions
PMSPMDD
Interventions
DRUG

LSD 10 μg every Day

Participants will receive 10 μg LSD every day during the luteal phase

DRUG

LSD 10 μg every other day

Participants receive 10μg LSD every second day during the luteal phase

DRUG

Placebo

Participants receive inactive placebo during the luteal phase

Trial Locations (1)

4056

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel

All Listed Sponsors
lead

Friederike Holze

OTHER

NCT07189299 - Microdosing LSD in Women With Premenstrual Disorders | Biotech Hunter | Biotech Hunter